Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/31303
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2023-03-02T11:33:04Z-
dc.date.available2023-03-02T11:33:04Z-
dc.date.issued2016-09-22-
dc.identifier.citationYılmaztepe, O. A. vd. (2017). ''Combination of esomeprazole with chemotherapeutics results in more pronounced cytotoxic effect via apoptosis on A549 nonsmall-cell lung cancer cell line''. Turkish Journal of Biology, 41(1), 231-241.tr_TR
dc.identifier.issn1300-0152-
dc.identifier.issn1303-6092-
dc.identifier.urihttps://doi.org/10.3906/biy-1606-46-
dc.identifier.urihttps://journals.tubitak.gov.tr/biology/vol41/iss1/24/-
dc.identifier.urihttp://hdl.handle.net/11452/31303-
dc.description.abstractThe vacuolar (H+)-ATPases that pump H+ from the cytoplasm to extracellular compartments can alter the pH of the tumor microenvironment. Esomeprazole can effectively inhibit vacuolar (H+)-ATPases and may increase the effectiveness of chemotherapeutics. Therefore, we used esomeprazole in combination with cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine on the A549 nonsmall-cell lung cancer cell line. Cisplatin and carboplatin combinations with esomeprazole exhibited superior cytotoxicity compared to the other selected chemotherapeutics. Low-dose combinations of esomeprazole with either cisplatin or carboplatin resulted in synergistic interaction. We examined cytotoxic activity of these combinations with the xCELLigence real-time cytotoxicity assay and detected that esomeprazole combinations with both 100% test drug concentrations of cisplatin and carboplatin shifted the antiproliferative effects of these agents towards a cytotoxic effect in a dose-dependent manner. Cell death mode was investigated by M30 assay, Annexin-V-FITC fluorescence imaging, and determination of PARP cleavage in western blotting. The cells treated with the cisplatin and esomeprazole combination displayed characteristic features of apoptosis such as elevated M30 levels, Annexin-V staining, and PARP cleavage. In conclusion, these novel combinations resulted in higher sensitivity of tumors to chemotherapeutics, thereby warranting further in vivo experiments for proof of the concept.en_US
dc.language.isoenen_US
dc.publisherTÜBİTAKtr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectLife sciences & biomedicine - other topicsen_US
dc.subjectLung carcinomaen_US
dc.subjectCisplatinen_US
dc.subjectCarboplatinen_US
dc.subjectEsomeprazoleen_US
dc.subjectApoptosisen_US
dc.subjectSynergismen_US
dc.subjectProton pump inhibitorsen_US
dc.subjectVacuolar h+-atpaseen_US
dc.subjectTumor acidityen_US
dc.subjectDrug-combinationen_US
dc.subjectHuman-melanomaen_US
dc.subjectBreast-canceren_US
dc.subjectSolid tumorsen_US
dc.subjectPhen_US
dc.subjectResistanceen_US
dc.subjectPharmacokineticsen_US
dc.titleCombination of esomeprazole with chemotherapeutics results in more pronounced cytotoxic effect via apoptosis on A549 nonsmall-cell lung cancer cell lineen_US
dc.typeArticleen_US
dc.identifier.wos000394539800024tr_TR
dc.identifier.scopus2-s2.0-85013499338tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.relation.bapT(U)-2009/08tr_TR
dc.contributor.orcid0000-0003-0463-6818tr_TR
dc.contributor.orcid0000-0003-2647-5875tr_TR
dc.contributor.orcid0000-0003-0297-846Xtr_TR
dc.identifier.startpage231tr_TR
dc.identifier.endpage241tr_TR
dc.identifier.volume41tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalTurkish Journal of Biologyen_US
dc.contributor.buuauthorYılmaztepe, Oral Arzu-
dc.contributor.buuauthorOral, Haluk Barbaros-
dc.contributor.buuauthorSarımahmut, Mehmet-
dc.contributor.buuauthorCevatemre, Buse-
dc.contributor.buuauthorÖzkaya, Güven-
dc.contributor.buuauthorKorkmaz, Şeniz-
dc.contributor.buuauthorUlukaya, Engin-
dc.contributor.researcheridK-7285-2012tr_TR
dc.contributor.researcheridAAG-8288-2021tr_TR
dc.contributor.researcheridA-4421-2016tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.indexed.trdizinTrDizintr_TR
dc.subject.wosBiologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid26425326300tr_TR
dc.contributor.scopusid7004498001tr_TR
dc.contributor.scopusid44661687400tr_TR
dc.contributor.scopusid55693788600tr_TR
dc.contributor.scopusid16316866500tr_TR
dc.contributor.scopusid36666461900tr_TR
dc.contributor.scopusid6602927353tr_TR
dc.subject.scopusH-Transporting ATP Synthase; Proton Pump Inhibitors; Bafilomycin A1en_US
Appears in Collections:Scopus
TrDizin
Web of Science

Files in This Item:
File Description SizeFormat 
Yılmaztepe_vd_2017.pdf3.07 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons